Literature DB >> 11856642

Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease.

M A Monroy1, F P Ross, S L Teitelbaum, M S Sands.   

Abstract

Mucopolysaccharidosis type VII (MPS VII) is a heritable lysosomal storage disease caused by a deficiency in beta-glucuronidase (GUSB) activity, leading to progressive accumulation of undegraded glycosaminoglycans in many tissues. Clinical features include growth and mental retardation, hearing and visual defects, shortened lifespan, and skeletal deformities. A murine model of MPS VII has been described that shares many of the manifestations of the human disease, including the skeletal dysplasia. In this study we describe abnormalities in the cellular morphology and function of osteoclasts and a localized defect in bone formation rate in the MPS VII mouse. Ultrastructural analysis revealed that MPS VII osteoclasts fail to form ruffled border membranes and many appeared to be detached from the bone surface. Following bone marrow transplantation, osteoclasts derived from wild-type donors showed normal morphology and were closely associated with the bone surface in MPS VII recipients. In vitro bone resorption assays demonstrated that MPS VII osteoclasts formed significantly smaller and fewer pits than those formed by osteoclasts derived from normal mice of the same strain. Although osteoclast morphology and function appeared to be abnormal in the MPS VII mouse, interleukin-1 (IL-1)-induced osteoclastogenesis in vivo was not affected. In addition to the osteoclast defects, MPS VII mice demonstrated a slower rate of bone matrix deposition in the epiphysis by in vivo calcein labeling experiments. These data suggest that abnormal morphology and function of MPS VII osteoclasts, combined with deficient matrix deposition, may contribute to the skeletal defects observed in this lysosomal storage disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11856642     DOI: 10.1016/s8756-3282(01)00679-2

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  22 in total

1.  Factors that affect postnatal bone growth retardation in the twitcher murine model of Krabbe disease.

Authors:  Miguel Agustin Contreras; William Louis Ries; Srinivasan Shanmugarajan; Gonzalo Arboleda; Inderjit Singh; Avtar Kaur Singh
Journal:  Biochim Biophys Acta       Date:  2010-05-02

2.  [Mucopolysaccharidoses].

Authors:  B Link; E Miebach; T Vetter; D Schmitt; M Beck; A Meurer
Journal:  Orthopade       Date:  2008-01       Impact factor: 1.087

3.  Potential role of cathepsin K in the pathophysiology of mucopolysaccharidoses.

Authors:  Susan Wilson; Dieter Brömme
Journal:  J Pediatr Rehabil Med       Date:  2010

Review 4.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

5.  Growth patterns and the use of growth hormone in the mucopolysaccharidoses.

Authors:  L E Polgreen; B S Miller
Journal:  J Pediatr Rehabil Med       Date:  2010

6.  Biomarkers of bone remodeling in children with mucopolysaccharidosis types I, II, and VI.

Authors:  David A Stevenson; Kyle Rudser; Alicia Kunin-Batson; Ellen B Fung; David Viskochil; Elsa Shapiro; Paul J Orchard; Chester B Whitley; Lynda E Polgreen
Journal:  J Pediatr Rehabil Med       Date:  2014

7.  Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities.

Authors:  Susan Wilson; Saadat Hashamiyan; Lorne Clarke; Paul Saftig; John Mort; Valeria M Dejica; Dieter Brömme
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

8.  Effect of recombinant human growth hormone on changes in height, bone mineral density, and body composition over 1-2 years in children with Hurler or Hunter syndrome.

Authors:  Lynda E Polgreen; William Thomas; Paul J Orchard; Chester B Whitley; Bradley S Miller
Journal:  Mol Genet Metab       Date:  2013-12-11       Impact factor: 4.797

9.  Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease.

Authors:  Todd E Meyerrose; Marie Roberts; Kevin K Ohlemiller; Carole A Vogler; Louisa Wirthlin; Jan A Nolta; Mark S Sands
Journal:  Stem Cells       Date:  2008-04-24       Impact factor: 6.277

Review 10.  Pathogenesis and treatment of spine disease in the mucopolysaccharidoses.

Authors:  Sun H Peck; Margret L Casal; Neil R Malhotra; Can Ficicioglu; Lachlan J Smith
Journal:  Mol Genet Metab       Date:  2016-06-04       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.